View printer-friendly version
« Back
July 13, 2012 12:49 p.m.
Teva to Report Second Quarter 2012 Financial Results on August 2, 2012

JERUSALEM, Israel--(BUSINESS WIRE)--Jul. 13, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its second quarter 2012 financial results on Thursday, August 2, 2012 at 7:00 a.m. EDT.

Teva will host a conference call and live webcast on the same day, at 8:00 a.m. EDT to discuss its second quarter 2012 results and overall business environment. A Question & Answer session will follow this discussion.

In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States and Canada 1-888-713-4205; International 617-213-4862; passcode: 68430667.

A live webcast of the call will also be available on Teva's website at: http://www.tevapharm.com. Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software. Participants may preregister for the call at: http://www.theconferencingservice.com/prereg/key.process?key=PW6YQWDV4

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on the Company's website. The replay can also be accessed until August 9, 2012, at 11:59 p.m. ET by calling 1-888-286-8010 or 617-801-6888; passcode: 26396486.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $18.3 billion in net revenues in 2011.

Source: Teva Pharmaceutical Industries Ltd.